ABBISKO CAYMAN DL-00001 Total Assets
ABBISKO CAYMAN DL-00001 total assets. Based on the latest financial reports, ABBISKO CAYMAN DL-00001 (8ZD) holds total assets worth €2.35 Billion EUR (≈ $2.75 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 8ZD market cap for the company's overall valuation and market capitalisation.
Total Assets of ABBISKO CAYMAN DL-00001 (2021–2025)
Total assets of ABBISKO CAYMAN DL-00001 from 2021 to 2025. This chart illustrates how ABBISKO CAYMAN DL-00001's total assets have evolved over time, based on quarterly financial data. See ABBISKO CAYMAN DL-00001 share price for real-time trading data and today's change.
ABBISKO CAYMAN DL-00001 - Asset Composition Analysis
ABBISKO CAYMAN DL-00001 Total Assets Breakdown (December 2025)
ABBISKO CAYMAN DL-00001 total assets breakdown as of December 2025. ABBISKO CAYMAN DL-00001's total assets of €2.35 Billion consist of 90.4% current assets and 9.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 31.8% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €4.20 Million | 0.2% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how ABBISKO CAYMAN DL-00001's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ABBISKO CAYMAN DL-00001 short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ABBISKO CAYMAN DL-00001's current assets represent 90.4% of total assets in 2025, a decrease from 97.2% in 2021.
- Cash Position: Cash and equivalents constituted 31.8% of total assets in 2025, down from 95.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 0.2% of total assets.
ABBISKO CAYMAN DL-00001 Competitors by Total Assets
Key competitors of ABBISKO CAYMAN DL-00001 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
ABBISKO CAYMAN DL-00001 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.98 | 14.92 | 21.75 |
| Quick Ratio | 4.98 | 14.92 | 21.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.70 Billion | €1.88 Billion | €2.09 Billion |
ABBISKO CAYMAN DL-00001 - Advanced Valuation Insights
This section examines the relationship between ABBISKO CAYMAN DL-00001's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.67 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | 11.7% |
| Total Assets | €2.35 Billion |
| Market Capitalization | $566.33 Million USD |
Valuation Analysis
Below Book Valuation: The market values ABBISKO CAYMAN DL-00001's assets below their book value (0.24x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: ABBISKO CAYMAN DL-00001's assets grew by 11.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ABBISKO CAYMAN DL-00001 (2021–2025)
The table below shows the annual total assets of ABBISKO CAYMAN DL-00001 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €2.35 Billion ≈ $2.75 Billion |
+11.68% |
| 2024-12-31 | €2.11 Billion ≈ $2.46 Billion |
-0.39% |
| 2023-12-31 | €2.12 Billion ≈ $2.47 Billion |
-15.03% |
| 2022-12-31 | €2.49 Billion ≈ $2.91 Billion |
-6.22% |
| 2021-12-31 | €2.65 Billion ≈ $3.10 Billion |
-- |
About ABBISKO CAYMAN DL-00001
Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus … Read more